MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA) and the Bill & Melinda Gates Medical Research Institute (Gates MRI) announced a licensing agreement for two preclinical antibacterial candidates for evaluation as potential components of combination regimens for the treatment of tuberculosis (TB).